1Di Gennaro E,Bruzzese F,Caraglia M,et al. Acetylation of proteins as novel target for antitumor therapy. Amino Acids,2004,26(4) :435-441.
2Moe behrens GH, Pandolfi PP. Targeting aberrant transcriptional repression in acute myeloid leukemia. Rev Clin Exp Hematol, 2003,7(2) :139-159.
3Okuno M, Kojima S, Akita K, et al. Retinoids in liver fibrosis and cancer. Front Biosci ,2002,7 :d204-218.
4Gu BW,Xiong H,Zhou Y ,et al. Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia:use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proc Natl Acad Sci USA,2002,99( 11 ):7640-7645.
5Wang ZY. Mechanism of action of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia. Gan to Kagaku Ryoho,2002,29 ( Suppl 1 ) :214-218.
6Vigushin DM, Coombes RC. Targeted histone deacetylase inhibition for cancer therapy. Curt Cancer Drug Targets,2004,4(2):205-218.
7Cote S, Rosenauer A, Bianchina A, et al. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood ,2002,100 (7) :2586-2596.
8He LZ,Tolentino T, Grayson P, et al. Histone deacetylase inhibitors induce remission in transgenic modds of therapy-resistant acute promyelocytic leukemia.J Clin Invest.2001.108(9):1321-1330.
9Lase A,Carnicer MJ,Aventin A,et al. MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia,2004,18 (7) : 1231-1237.
10Oligny LL. Cancer and epigenesis:a developmental perspective. Adv Pediatr, 2003,50:59-80.
